OncoZenge
4.67
SEK
+0.43 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+0.43%
-22.55%
-33.29%
+24.53%
-54.75%
+19.9%
+108.48%
-
-61.84%
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Read moreMarket cap
54.7M SEK
Turnover
59.1K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
15/5
2025
Interim report Q1'25
28/5
2025
General meeting '25
21/8
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
OncoZenge AB: OncoZenge Provides Update on Regulatory Status for Incoming Investment
OncoZenge AB publicerar årsredovisning för 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools